PTC Therapeutics (PTCT) Reiterated at Overweight by Cantor Fitzgerald
July 15, 2026 7:51 AM
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $124.00 price target on PTC Therapeutics (NASDAQ: PTCT).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
